COVID-19 : From Bench to Bedside book cover
1st Edition

From Bench to Bedside

ISBN 9781032040622
Published March 4, 2022 by CRC Press
238 Pages 30 Color & 2 B/W Illustrations

FREE Standard Shipping
USD $84.95

Prices & shipping based on shipping country


Book Description

The COVID-19 pandemic has affected the entire world in an unprecedented way, and this book provides an overview of the historical facts as well as ongoing approaches to tackle the COVID-19 pandemic. Experts of the respective domains provide details on anti-SARS-CoV-2 drug strategies, including repurposing drugs used for other indications and the development of novel drugs looking at different approaches to target virus entry and replication. COVID-19 vaccine development based on inactivated and attenuated live virus, protein subunit and peptide-based vaccines and utilization of vaccine candidates based on viral vectors, DNA and RNA are presented for both preclinical studies and clinical trials.

Key Features

  • Explains the background of the COVID-19 pandemic, the current progress in the development of treatments and prevention of COVID-19 including future aspects of dealing with the pandemic
  • Serves as a timely repository of knowledge on COVID-19 for researchers and medical professionals engaged in its management

Table of Contents

Chapter 1 Coronavirus epidemics and the current COVID-19 pandemic
Aparna Bhardwaj, Prateek Kumar, Shivani Krishna Kapuganti, Vladimir N. Uversky, and Rajanish Giri

Chapter 2 Biology of Coronaviruses and Predicted Origin of SARS-CoV-2
Giorgio Palù, Alberto Reale, Nicolas G. Bazan, Pritam Kumar Panda, Vladimir N. Uversky, Murat Seyran, Alaa A. A. Aljabali, Samendra P. Sherchan, Gajendra Kumar Azad, Wagner Baetas-da-Cruz, Parise Adadi, Murtaza M. Tambuwala, Bruce D. Uhal, Kazuo Takayama, Ángel Serrano-Aroca, Tarek Mohamed Abd El-Aziz1, Adam M. Brufsky and Kenneth Lundstrom

Chapter 3 Therapeutic Challenges in COVID-19
Alaa A. A. Aljabal1, Murtaza M. Tambuwala, Debmalya Barh and Kenneth Lundstrom

Chapter 4 Prevention and Control Strategies for COVID-19 Pandemic
Isfendiyar Darbaz, Gizem Morris, and Şükrü Tüzmen

Chapter 5 Global Focus and Interdisciplinary Approaches in COVID-19 Research and Their Outcomes
Hülya Şenol and Şükrü Tüzmen

Chapter 6 The evolution of COVID-19 diagnostics
Praveen Rai, Ballamoole Krishna Kumar, Deekshit Vijaya Kumar, Prashant Kumar, Anoop Kumar, Shashi Kumar Shetty and Biswajit Maitia

Chapter 7 Drug repurposing and novel antiviral drugs for COVID-19 management
Shailendra Dwivedi, Aakanksha Rawat, Amit Ranjan, Ruchika Agrawal, Radhieka Misra, Sunil Kumar Gupta, Surekha Kishore and Sanjeev Misra

Chapter 8 Convalescent Plasma and Antibody Therapy in COVID-19
Didem Rıfkı, Eymen Ü. Kılıç and, Şükrü Tüzmen

Chapter 9 Application Stem Cell and Exosome Based Therapy in COVID-19
Suleyman Gokhan Kara and Ayla Eker Sariboyaci

Chapter 10 Host and Pathogen-Specific Drug Targets in COVID-19
Bruce D. Uhal, David Connolly, Farzaneh Darbeheshti, Yong-Hui Zheng, Ifeanyichukwu E. Eke. Yutein Chung and Lobelia Samavati

Chapter 11 Computational biology and bioinformatics in anti-SARS-CoV-2 drug development
Vladimir N. Uversky

Chapter 12 Nanomaterials in COVID-19 drug development
Alaa A A Aljabali, Ángel Serrano-Aroca and Murtaza M. Tambuwala

Chapter 13 Vaccine Development Strategies and the Current Status of COVID-19 Vaccines
Mohsen Akbarian, Kenneth Lundstrom, Elrashdy M. Redwan and Vladimir N. Uversky

Chapter 14 Clinical trials of COVID-19 therapeutics and vaccines: history, current status, and limitations
Candan Hizel Perry, Havva Ö. Kılgöz and Şükrü Tüzmen

Chapter 15 Lessons Learned from COVID-19 and Their Implementations for Future Pandemics
Mauricio Corredor, Debmalya Barh and Kenneth Lundstrom

View More



Dr. Debmalya Barh is currently a Visiting Full Professor (Titular, Grade-E) at the Department of Genetics, Ecology and Evolution, Institute of Biological Sciences (ICB), Federal University of Minas Gerais (UFMG), Brazil. He is also an honorary Scientist at Institute of Integrative Omics and Applied Biotechnology (IIOAB), India.

Dr. Kenneth Lundstrom is currently the CEO of PanTherapeutics in Lausanne, Switzerland.He serves on editorial boards of various journals including Biomedicines and Viruses, and acts as Editor-in-chief for Frontiers in Translational Virology.